Shakur-Still, Haleema; Roberts, Ian; Fawole, Bukola; Kuti, Modupe; Olayemi, Oladapo O; Bello, Adenike; Huque, Sumaya; Ogumbode, Olayinka; Kotila, Taiwo; Aimakhu, Chris; +8 more... Okunade, Olujide A; Olutogun, Tolulase; Adetayo, Cecilia O; Dallaku, Kastriot; Mansmann, Ulrich; Hunt, Beverley J; Pepple, Tracey; Balogun, Eni; (2018) Effect of tranexamic acid on coagulation and fibrinolysis in women with postpartum haemorrhage (WOMAN-ETAC): a single-centre, randomised, double-blind, placebo-controlled trial. Wellcome open research, 3. 100-. ISSN 2398-502X DOI: https://doi.org/10.12688/wellcomeopenres.14722.1

Downloaded from: http://researchonline.lshtm.ac.uk/id/eprint/4649883/

DOI: https://doi.org/10.12688/wellcomeopenres.14722.1

Usage Guidelines:

Please refer to usage guidelines at https://researchonline.lshtm.ac.uk/policies.html or alternatively contact researchonline@lshtm.ac.uk.

Available under license: http://creativecommons.org/licenses/by/2.5/
RESEARCH ARTICLE

Effect of tranexamic acid on coagulation and fibrinolysis in women with postpartum haemorrhage (WOMAN-ETAC): a single-centre, randomised, double-blind, placebo-controlled trial [version 1; referees: 2 approved]

Haleema Shakur-Still , Ian Roberts , Bukola Fawole , Modupe Kuti , Oladapo O. Olayemi , Adenike Bello , Sumaya Huque , Olayinka Ogunbode , Taiwo Kotila , Chris Aimakhu , Olujide A. Okunade , Tolulase Olutogun , Cecilia O. Adetayo , Kastriot Dallaku , Ulrich Mansmann , Beverly J. Hunt  , Tracey Pepple , Eni Balogun

Abstract

Background: Postpartum haemorrhage (PPH) is a leading cause of maternal death. The WOMAN trial showed that tranexamic acid (TXA) reduces death due to bleeding in women with PPH. We evaluated the effect of TXA on fibrinolysis and coagulation in a sample of WOMAN trial participants.

Methods: Adult women with a clinical diagnosis of PPH were randomised to receive 1 g TXA or matching placebo in the WOMAN trial. Participants in the WOMAN trial at University College Hospital (Ibadan, Nigeria) also had venous blood taken just before administration of the first dose of trial treatment and again 30 (±15) min after the first dose (the ETAC study). We aimed to determine the effects of TXA on fibrinolysis (D-dimer and rotational thromboelastometry maximum clot lysis (ML)) and coagulation (international normalized ratio and clot amplitude at 5 min). We compared outcomes in women receiving TXA and placebo using linear regression, adjusting for baseline measurements.

Results: Women (n=167) were randomised to receive TXA (n=83) or matching placebo (n=84). Due to missing data, seven women were excluded from analysis. The mean (SD) D-dimer concentration was 7.1 (7.0) mg/l in TXA-treated women and 9.6 (8.6) mg/l in placebo-treated women (p=0.09). After adjusting for baseline, the D-dimer concentration was 2.16 mg/l lower in TXA-treated women. D-dimer was 2.16 mg/l lower in TXA-treated women (95% CI -4.31 to 0.00, p=0.05).

Referee Status: Invited Referees

Invited Referees

1 Homa K. Ahmadzia, George Washington University , USA

2 Stanislas Grassin-Delyle , University of Paris-Saclay, France

Open Peer Review

Discuss this article

Comments (0)
TXA-treated women (-2.16, 95% CI -4.31 to 0.00, p=0.05). There was no significant difference in ML between TXA- and placebo-treated women (12.3% (18.4) and 10.7% (12.6), respectively; p=0.52) and no significant difference after adjusting for baseline ML (1.02, 95% CI -3.72 to 5.77, p=0.67). There were no significant effects of TXA on any other parameters.

Conclusion: TXA treatment was associated with reduced D-dimer levels but had no apparent effects on thromboelastometry parameters or coagulation tests.

Registration: ISRCTN76912190 (initially registered 10/12/2008, WOMAN-ETAC included on 22/03/2012) and NCT00872469 (initially registered 31/03/2009, WOMAN-ETAC included on 22/03/2012).

Keywords
Postpartum Haemorrhage, Fibrinolysis, Coagulation, Tranexamic Acid, Randomised Controlled Trial, Thromboelastogram
The aims and methods of the WOMAN (fibrinolysis) thus reducing the severity of bleeding and the risk of hypothesised that TXA would reduce fibrin clot breakdown at the University College Hospital, Ibadan, Nigeria. We conducted a per-protocol analysis that included all participants who satisfied the eligibility criteria, received the allocated treatment, had follow up samples and at least one measurement placebo by intravenous injection. If bleeding continued after 30 min, or if bleeding stopped and restarted within 24 h, a second dose of 1 g of TXA or placebo was given. We collected patient entry and outcome data as per the WOMAN trial protocol.

Participants and blood sampling
WOMAN trial participants at University College Hospital, Ibadan, Nigeria were also considered for inclusion in the ETAC trial. In addition to the WOMAN trial procedures, women had 15 ml venous blood taken after randomisation and before administration of the first dose of trial treatment. A second venous blood sample of about 15 ml was taken 30 (±15) min after the first dose and before a second dose was given.

Sample analysis
We divided each venous blood sample into three vacutainer tubes. We collected one 5 ml sample in a tube containing potassium EDTA for full blood count analysis and two 4.5 ml samples in tubes containing 0.5 ml sodium citrate (0.109 mol/l) for coagulation and rotational thromboelastometry (ROTEM). We used a five-parameter particle counter Sysmex KN analyser (Sysmex Corporation, Kobe, Japan) for the full blood count analysis.

After centrifuging the blood at 3000g for 20 min, we extracted the plasma without disturbing the buffy coat layer, and measured prothrombin time (PT), activated partial thromboplastin time (APTT), Clauss fibrinogen and D-dimers using a HumaClot Junior automated coagulation analyser. We measured ROTEM parameters at 37°C using two of the four channels (EXTEM, APTEM) of the ROTEM coagulation analyser (TEM®, Munich, Germany)). The ROTEM was allowed to run for 60 min. The following ROTEM variables were examined from the EXTEM and APTEM traces: clotting Time, clot amplitude at 5 and 10 min (CA-5, CA-10), maximum clot firmness (MCF), maximum clot lysis (ML) and lysis index (LI). We stored the ROTEM reagents at 2–8°C with temperature monitoring and we used in-date reagents. The clinical staff had no access to the results of ROTEM analysis carried out for the ETAC trial.

In addition, we collected the following information: time of blood samples, time the trial treatment was administered, time laboratory analysis started and ended, any treatment given that may affect coagulation, adverse events, and technical problems with analysis.

Analyses
We published a statistical analysis plan before the allocation was unblinded. We assumed that D-dimer mean and standard deviation in the control group would be 9,000 ng/ml and 7,200 ng/ml, respectively. Taking into account that we would adjust for baseline measurement and assuming a correlation between baseline and follow-up of 0.4, we estimated that a study with about 180 patients would have 90% power (two-sided alpha=5%) to detect a reduction of 30% in the mean D-dimer value in the tranexamic group.

We conducted a per-protocol analysis that included all participants who satisfied the eligibility criteria, received the allocated treatment, had follow up samples and at least one measurement.
of the primary outcome. We did not exclude outliers or impute missing data as it would be inappropriate in a study aimed at understanding the biological effects of TXA.

Outcomes
We assessed the effect of TXA on fibrinolysis by assessing D-dimer and ML as our co-primary outcome. For each co-primary outcome, we compared the follow up results of each treatment group (t-test).

Our secondary outcomes included INR, PT, APTT, fibrinogen, haemoglobin and the following ROTEM EXTEM parameters: clotting time (CT), clot amplitude at 5 (A5) and 10 min (A10), LI at 30 and 60 min and MCF. We compared the mean follow-up result in women receiving TXA and those receiving placebo using the t-test. We also compared follow-up results of each treatment group using linear regression, adjusting for the corresponding baseline measurement.

Statistical analysis
The effect of TXA on our co-primary outcomes, D-dimer and maximum lysis, were explored stratified by time since delivery, type of delivery, cause of postpartum haemorrhage and maternal anaemia. A t-test was conducted to compare means between treatment arms, and the likelihood ratio test was used to test for interaction between subgroups. We defined hyperfibrinolysis as ML>15% on ROTEM EXTEM and coagulopathy as an INR >1.2 and A5 ≤40 mm. We used logistic regression to assess multivariate odds ratios between baseline variables and hyperfibrinolysis and coagulopathy. Stata 15 was used for all statistical analyses.

To set the results of the ETAC study in context of an almost identical haematological sub-study conducted within the WOMAN trial but in a different location (Albania) and provide a more robust estimate of the effect of TXA on D-dimer, we conducted a meta-analysis of the two studies. Data from the ETAC trial and ETAPlaT (a single centre sub-study of the WOMAN trial) were pooled. Eligibility criteria for both trials were the same and blood samples were collected for D-dimer in the same way in both trials. We computed the pooled ratio of D-dimers in women receiving TXA compared to women receiving placebo. We log-transformed individual patient data for D-dimer, and calculated the arithmetic mean (SD) of the log-transformed values for each study. A meta-analysis of the arithmetic means of transformed data gives a mean difference, which after back-transforming, corresponds to a meta-analysis of the ratio of geometric means in the original scale. Statistical heterogeneity was examined by visual inspection of forest plots, the I² statistic and χ² test. This analysis was not included in the statistical analysis plan for the ETAC trial.

Ethical approval and consent to participate
The trial was conducted in accordance with the ICH-GCP[17]. Approvals were obtained from the Ethics Committees of London school of Hygiene and Tropical Medicine (Reference A275 5536) and the University of Ibadan & University College Hospital Ethics Committee (Reference UI/EC/09/0131). Regulatory approval was obtained from the Nigerian National Agency for Food and Drug Administration and Control.

The consent procedures are described in detail in the WOMAN Trial protocol[17]. In summary, consent was obtained from women if their physical and mental capacity allowed. If a woman was unable to give consent, proxy consent was obtained from a relative or representative. If a proxy was unavailable, then consent was deferred or waived. When consent was deferred or given by a proxy, the woman was informed about the trial as soon as possible, and consent obtained for on-going data collection, if needed.

Results
Participation
The ETAC trial recruited patients from April 2012 to March 2016. A total of 205 women were recruited into the WOMAN trial at University College Hospital, Ibadan during this period of whom 167 were included in the ETAC trial. The planned sample size of 180 participants was not reached due to occasional equipment failures and interruptions in the supply of reagents. Participants were randomly assigned to receive TXA (n=83) or placebo (n=84). All participants received the first dose of the allocated treatment, and no one withdrew their consent. Data on both co-primary outcomes were missing for 7 women, and they were excluded from the primary analysis. The CONSORT flow diagram is shown in Figure 1. The dataset generated for this study is available online following registration[17].

Participant characteristics
Table 1 reports baseline characteristics of trial participants by treatment group. A total of 128 (77%) gave birth in the hospital, whereas 39 (23%) gave birth in other settings and were admitted to hospital after PPH onset. Age and systolic blood pressure were normally distributed; all other continuous variables had a skewed distribution. Therefore, we present means, medians and interquartile ranges for all variables. The mean ROTEM CT at baseline was higher in women randomised to TXA (180 s) compared to placebo (78 s). All other baseline parameters were similar between the two treatment arms.

Follow-up venous blood was collected at 31 (6) (mean (SD)) minutes after administration of TXA or matching placebo and all samples were obtained before a second dose was given. The mean (SD) time between treatment and collection of the follow up blood sample was 30 (4) min in the TXA arm and 33 (8) minutes in the placebo arm.

The effect of TXA on fibrinolysis and coagulation is reported in Table 2. The mean (SD) D-dimer level after treatment was 7.1 (7.0) mg/l in women receiving TXA and 9.6 (8.6) in women receiving the placebo. After adjusting for baseline D-dimer level, the difference in mean D-dimer between women receiving TXA and placebo was -2.16 (95% CI: -4.31 to 0.00, p=0.05). There was no significant difference in ML between TXA- and placebo-treated women (12.3% (18.4) and 10.7% (12.6), respectively; p = 0.52) and no significant difference after adjusting for baseline ML (1.02, 95% CI -3.72 to 5.77, p= 0.67).
167 patients enrolled and randomly assigned

83 assigned to receive tranexamic acid
0 withdrew consent after randomisation
83 baseline data available
83 received allocated dose 1
3 no follow-up (27 patients did not have data for d-dimer; 5 patients did not have data for ML)
80 included in analysis of primary outcomes

84 assigned to receive placebo
0 withdrew consent after randomisation
84 baseline data available
84 received allocated dose 1
4 no follow-up (26 patients did not have data for d-dimer; 8 patients did not have data for ML)
80 included in analysis of primary outcomes

Table 1. Baseline characteristics by treatment group (N=167).

|                          | TXA (N = 83) | Placebo (N = 84) |
|--------------------------|--------------|------------------|
|                          | n*           | Mean (SD)/       | Median (IQR)     |
|                          | count (%)    | Mean (SD)/       | Median (IQR)     |
| Age                      | 83           | 32.1 (5.8)       | 32 (29, 36)      |
| >35 years                | 28 (33.7%)   | 21 (25.0%)       |
| Time since delivery      | 83           | 4.5 (6.2)        | 1.7 (0.8, 6.3)   |
| ≤3 hours                 | 52 (62.7%)   | 51 (60.7%)       |
| >3 hours                 | 31 (37.3%)   | 33 (39.3%)       |
| Type of delivery         | 83           | 46 (55.4%)       | 41 (48.8%)       |
| Vaginal                  | 37 (44.6%)   | 43 (51.2%)       |
| Caesarean section        | 46 (55.4%)   | 41 (48.8%)       |
| Delivery in randomising hospital | 83           |                   |
| Yes                      | 62 (74.7%)   | 66 (78.6%)       |
| No                       | 21 (25.3%)   | 18 (21.4%)       |
| Cause of Haemorrhage     | 83           | 84               |
| Uterine Atony            | 41 (49.4%)   | 33 (39.3%)       |
| Other                    | 42 (50.6%)   | 51 (60.7%)       |
| Systolic blood pressure (mmHg) | 83           | 108.2 (26.7)     |
| <90 mmHg                 | 17 (20.5%)   | 14 (16.9%)       |
|                             | TXA (N = 83) | Placebo (N = 84) |
|-----------------------------|--------------|-----------------|
| Blood loss volume          | n            | Mean (SD)/Count (%) | Median (IQR) |
| >1000 ml                   | 83           | 1638.9 (1016.9)   | 1300 (1000, 2000) |
| Clinical signs of shock    | n            | 56 (67.5%)       | 52 (61.9%)     |
| Yes                        | 83           | 54 (65.1%)       | 51 (60.7%)     |
| No                         | 29 (34.9%)   | 33 (39.3%)       |               |
| Full Blood Count Variables |               |                  |               |
| Haemoglobin (g/l)          | n            | 65               | 67             |
| <110 g/l                   | 72.6 (32.6)  | 63.4 (37.8)      | 84 (63, 100)   |
| White cell count (x10⁹/l) | n            | 12.2 (7.6)       | 11.7 (8.7)     |
| Platelet count (x10⁹/l)    | n            | 151.6 (114.9)    | 158.9 (87.2)   |
| Coagulation Variables      |               |                  |               |
| INR                        | n            | 67               | 70             |
| INR>1.2                    | 1.6 (1.4)    | 1.4 (0.8)        | 1.1 (1.0, 1.3) |
| PT (s)                     | n            | 67               | 70             |
| APTT (s)                   | 20.5 (15.6)  | 17.6 (8.6)       | 14.8 (13.5, 16.8) |
| Fibrinogen (g/l)           | n            | 66               | 65             |
| D-dimer (mg/l)             | 7.7 (8.6)    | 8.0 (6.1)        | 6.0 (3.3, 11.9) |
| Thromboelastometry (ROTEM® EXTEM) variables |               |                  |               |
| CT (seconds)               | n            | 73               | 78             |
| ML (%)                     | 17.0 (25.0)  | 12.6 (14.9)      | 9 (4, 14)      |
| ML>15%                     | 39.4 (18.0)  | 44.6 (13.2)      | 48 (38, 53)    |
| A5 (mm)                    | n            | 69               | 77             |
| A5<40                      | 39.4 (18.0)  | 44.6 (13.2)      | 48 (38, 53)    |
| A10 (mm)                   | n            | 69               | 77             |
| LIL30 (%)                  | 96.5 (15.6)  | 54.7 (13.6)      | 59 (51, 63)    |
| LIL60 (%)                  | n            | 69               | 77             |
| MCF (mm)                   | 56.1 (20.6)  | 62.0 (13.6)      | 65 (61, 69)    |

*Number of women with available data. Two women in the tranexamic acid arm had outlying ROTEM EXTEM clotting time values of 1814 and 3468 seconds. TXA, tranexamic acid; INR, international normalized ratio; PT, prothrombin time; APTT, activated partial prothromboplastin time; CT, clotting time; ML, maximum lysis; A5, clot amplitude at 5 min; LIL30, lysis index at 30 min; MCF, maximum clot firmness.

There were no significant effects of TXA on any other parameters. There were no adverse events associated with this sub-study reported.

There was no evidence of heterogeneity in the effect of TXA on fibrinolysis (D-dimer and ML) by time since delivery, type of delivery, cause of haemorrhage and severity of anaemia.

**Discussion**

TXA treatment was associated with reduced D-dimer levels, but had no apparent effects on ROTEM parameters or coagulation tests. The effect of TXA on D-dimer levels in this study is similar to that observed in an almost identical WOMAN trial sub-study that aimed to assess the effects of TXA on platelet function (ETAPLAT-study)\(^{16}\). The eligibility criteria for both studies were the same and blood samples for D-dimer were collected in the same way. When the results of the two sub-studies are pooled in a meta-analysis (Figure 2), there is a 26% reduction in D-dimer levels with TXA (pooled D-dimer ratio 0.74, 95% CI 0.60 to 0.93, p=0.008). These results concur with a study in France that showed the early increase in D-dimer values in women with PPH can be inhibited by TXA\(^{11}\).
### Table 2. Effect of tranexamic acid (TXA) on coagulation and fibrinolysis in women with postpartum haemorrhage.

|                     | TXA     | Placebo | Difference (95% CI) | p-value† | Baseline adjusted difference (95% CI)‡ | p-value‡ |
|---------------------|---------|---------|---------------------|----------|---------------------------------------|----------|
| **Mean (SD)**       | Mean (SD) |         |                     |          |                                       |          |
| **Primary outcomes**| n       | n       | D-dimer (mg/l)      | 56       | 7.1 (7.0)                             | -2.5 (-5.4, 0.4) | 0.09 | -2.2 (-4.3, 0.0) | 0.05 |
| ML (%)              | 78      | 12.3 (18.4) | 76                  | 10.7 (12.6) | 1.6 (-3.4, 6.7)                      | 0.52     | 1.0 (-3.7, 5.8) | 0.67 |
| **Secondary outcomes** |         |         |                     |          |                                       |          |
| INR                 | 71      | 1.6 (1.8) | 70                  | 1.2 (0.4) | 0.4 (-0.1, 0.8)                      | 0.09     | 0.4 (-0.1, 0.9) | 0.11 |
| PT (s)              | 71      | 18.5 (15.6) | 70                  | 15.8 (4.7) | 2.7 (-1.1, 6.5)                      | 0.17     | 2.5 (-1.6, 6.6) | 0.22 |
| APTT (s)            | 71      | 36.3 (20.7) | 69                  | 33.2 (12.6) | 3.0 (-2.7, 8.8)                      | 0.30     | 1.0 (-3.9, 5.8) | 0.69 |
| Fibrinogen (g/l)    | 68      | 8.8 (6.1) | 69                  | 8.8 (6.5) | -0.03 (-2.2, 2.1)                    | 0.98     | -1.1 (-2.3, 0.2) | 0.08 |
| Haemoglobin (g/l)   | 71      | 75.4 (30.9) | 67                  | 83.2 (31.1) | -7.8 (-18.3, 2.6)                    | 0.14     | -1.0 (-8.8, 6.8) | 0.79 |
| **Thromboelastometry (ROTEM® EXTEM)** |         |         |                     |          |                                       |          |
| CT (s)              | 78      | 151.3 (528.4) | 77                  | 104.7 (385.9) | 46.6 (-100.4, 193.6)                 | 0.53     | -8.8 (-150.1, 132.4) | 0.90 |
| A5 (mm)             | 75      | 39.5 (16.7) | 76                  | 45.3 (12.9) | -5.8 (-10.6, -1.0)                   | 0.02     | -2.0 (-5.7, 1.7) | 0.27 |
| A10 (mm)            | 78      | 49.6 (18.1) | 76                  | 55.3 (13.1) | -5.7 (-10.8, -0.7)                   | 0.03     | -1.7 (-5.9, 2.5) | 0.41 |
| LI30 (%)            | 71      | 98.3 (11.3) | 73                  | 99.2 (3.6) | -0.8 (-3.5, 1.9)                     | 0.54     | -0.9 (-3.9, 2.0) | 0.52 |
| LI60 (%)            | 49      | 93.6 (13.0) | 49                  | 93.3 (11.5) | 0.2 (-4.7, 5.2)                      | 0.92     | -0.3 (-5.6, 4.9) | 0.90 |
| MCF (mm)            | 72      | 57.4 (18.1) | 70                  | 62.6 (11.1) | -5.2 (-10.2, -0.2)                   | 0.04     | -1.8 (-6.2, 2.5) | 0.40 |

†p-value from t-test. *Adjusted for the corresponding baseline parameter e.g. effect of TXA on D-dimer adjusted for pre-treatment D-dimer values. †p-value from likelihood ratio test (linear regression). INR, international normalized ratio; PT, prothrombin time; APTT, activated partial prothromboplastin time; CT, clotting time; A5, clot amplitude at 5 min; LI30, lysis index at 30 min; MCF, maximum clot firmness.

![Figure 2. Forest plot of the effect of tranexamic acid (TXA) on D-dimer values in women with postpartum haemorrhage.](image)

Although we planned to include 180 women in our study, due to equipment and power failures, and interruptions in the supply of reagents, only 167 women were recruited. Power cuts are common in Nigeria and although back-up power packs were supplied with the ROTEM delta analyser, these also failed on occasions. ROTEM reagents have a short shelf-life and were sourced in Europe since they are not readily available in Nigeria. Moreover, due to technical problems with blood samples or measurement instruments, the number of women with useable outcome data was less than the number of women enrolled. As a result, the power of the study to detect differences between treatment arms was lower than anticipated.
This lack of power may at least partially explain the absence of any significant effects of TXA on thromboelastometry parameters and coagulation tests.

Increased fibrinolysis is common in women with PPH\(^{39}\). Our results show that this increase can be inhibited with TXA. Larger studies into the effects of TXA on fibrinolysis and coagulation in women with or at risk from PPH are required.

**Data availability**

The anonymised trial data is available from the freeBIRD data portal at [https://ctu-app.lshtm.ac.uk/freebird/index.php/data-sharing/downloads/woman-etac/](https://ctu-app.lshtm.ac.uk/freebird/index.php/data-sharing/downloads/woman-etac/) following free registration: [http://dx.doi.org/10.17037/DATA.0000078](http://dx.doi.org/10.17037/DATA.0000078). Data are available under an Open Data Commons Attribution License (ODC-By) licence.

The trial protocol, statistical analysis plan and trial publications will be made freely available at [http://www.txacentral.org/](http://www.txacentral.org/) and [http://womantrial.lshtm.ac.uk/](http://womantrial.lshtm.ac.uk/)

**Author contributions**

I.R. and H.S.S. conceived the study, contributed data cleaning, statistical analysis and writing of the manuscript. B.F. contributed to protocol development and had overall responsibility for the study at the trial site and review of the manuscript. O.O.O. contributed to protocol development and is the site principal investigator for WOMAN trial and review of the manuscript. M.K. contributed to the protocol development and was responsible for overseeing laboratory tests, laboratory standard operating procedures and staff training and review of the manuscript. A.B. contributed to protocol development and was responsible for data transfer and review of the manuscript. O.O. contributed to the protocol development, development of the standard operating procedures and was responsible for participant recruitment and review of the manuscript. T.K. contributed to the protocol development and was responsible for participant recruitment and review of the manuscript. T.K. contributed to the protocol development and was responsible for routine laboratory tests and review of the manuscript. S.H. conducted the statistical analysis and contributed to the writing of the manuscript. T.O. was responsible for overseeing laboratory tests, laboratory standard operating procedures and staff training and review of the manuscript. B.J.H. contributed to data cleaning and contributed to the writing of the manuscript. T.O., O.A.O. and C.O.A. carried out some laboratory tests and review of the manuscript. T.P. and E.B. assisted with data management and review of the manuscript.

All authors have read and approved the final version of the manuscript.

**Competing interests**

No competing interests were disclosed.

**Grant information**

The WOMAN trial was funded by London School of Hygiene and Tropical Medicine, Department of Health (UK) (grant number HICF-T2-0510-007), Wellcome Trust (grant number 094947), the Bill & Melinda Gates Foundation (grant number OPP1095618). An educational grant, equipment, training and consumables for ROTEM analysis was provided by TEM innovations GmbH, M.-Kollar-Str. 13–15, 81829 Munich, Germany to LSHTM and utilised fully at the University College Hospital, Ibadan.

_The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript._

**Acknowledgements**

We would like to thank the women and their families whose contribution made this trial possible. We would like to acknowledge the assistance of Oyebisi Eletu, Glory Ehikhale and Tosin Lawal who carried out some of the laboratory analysis.

**Supplementary information**

Supplementary File 1. Completed CONSORT checklist.

Click here to access the data.

**References**

1. World Health Organisation: WHO Recommendations for the Prevention and Treatment of Postpartum Haemorrhage. WHO. Geneva. 2012. [Reference Source](#)
2. Carroll G, Cuesta C, Abalos E, et al.: Epidemiology of postpartum haemorrhage: a systematic review. Best Pract Res Clin Obstet Gynaecol. 2008; 22(6): 999–1012. [PubMed Abstract](#) [Publisher Full Text](#)
3. WHO, UNFPA and The World Bank: Trends in maternal mortality: 1990 to 2010 [Publisher Full Text](#)
4. Ronsmans C, Graham WJ, Lancet Maternal Survival Series steering group: Maternal mortality: who, when, where, and why. Lancet 2006; 368(9542): 1189–200. [PubMed Abstract](#) [Publisher Full Text](#)
5. Say L, Chou D, Gemmill A, et al.: Global causes of maternal death: a WHO
systematic analysis. Lancet Glob Health. 2014; 2(6): e323–33.

6. Electronic Medicines Compendium: Summary of Product Characteristics: Tranexamic acid. (accessed 11 July 2018).

7. WOMAN Trial Collaborators: Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial. Lancet. 2017; 389(10084): 2105–2116. PubMed Abstract | Publisher Full Text

8. CRASH-2 trial collaborators, Shakur H, Roberts I, et al.: Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet. 2010; 376(9734): 23–32. PubMed Abstract | Publisher Full Text

9. CRASH-2 collaborators, Roberts I, Shakur H, et al.: The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial. Lancet. 2011; 377(9771): 1096–101, 1101.e1-2. PubMed Abstract | Publisher Full Text

10. Sawamura A, Hayakawa M, Gando S, et al.: Disseminated intravascular coagulation with a fibrinolytic phenotype at an early phase of trauma predicts mortality. Thromb Res. 2009; 124(5): 608–613. PubMed Abstract | Publisher Full Text

11. Kruithof EK, Tran-Thang C, Gudinchet A, et al.: Fibrinolysis in pregnancy: a study of plasminogen activator inhibitors. Blood. 1987; 69(2): 460–6. PubMed Abstract

12. Ducloy-Bouthors AS, Duhamel A, Kipnis E, et al.: Postpartum haemorrhage related early increase in D-dimers is inhibited by tranexamic acid: haemostasis parameters of a randomized controlled open labelled trial. Br J Anaesth. 2016; 116(5): 641–648. PubMed Abstract | Publisher Full Text

13. Shakur H, Elbourne D, Gülmezoglu M, et al.: The WOMAN Trial (World Maternal Antifibrinolytic Trial): tranexamic acid for the treatment of postpartum haemorrhage: an international randomised, double blind placebo controlled trial. Trials. 2010; 11: 40. PubMed Abstract | Publisher Full Text | Free Full Text

14. Shakur H, Fawole B, Kuti M, et al.: Effect of tranexamic acid on coagulation and fibrinolysis in women with postpartum haemorrhage (WOMAN-ETAC): protocol and statistical analysis plan for a randomized controlled trial [version 1; referees: 3 approved]. Wellcome Open Res. 2016; 1: 31. PubMed Abstract | Publisher Full Text | Free Full Text

15. StataCorp: Stata Statistical Software: Release 15. College Station, TX: StataCorp LLC. 2017.

16. Dallaku K, Shakur H, Roberts I, et al.: Effects of tranexamic acid on platelet function and thrombin generation (ETAPiAT): WOMAN trial sub-study [version 1; referees: 2 approved]. Wellcome Open Res. 2016; 1: 29. PubMed Abstract | Publisher Full Text | Free Full Text

17. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Guideline for Good Clinical Practice E6(R1). 1996.

18. Shakur-Still H, Roberts I, Fawole B, et al.: WOMAN-ETAC Dataset. [Internet] LSHTM Data Compass. London, United Kingdom: London School of Hygiene & Tropical Medicine. 2018. http://www.doi.org/10.17037/DATA.0000078

19. Roberts I, Shakur H, Fawole B, et al.: Haematological and fibrinolytic status of Nigerian women with post-partum haemorrhage. BMC Pregnancy Childbirth. 2018; 18(1): 143. PubMed Abstract | Publisher Full Text | Free Full Text
Open Peer Review

Current Referee Status: ✔ ✔

Version 1

Referee Report 24 September 2018
doi:10.21956/wellcomeopenres.16038.r33855

Stanislas Grassin-Delyle
Foch Hospital, Respiratory Diseases Department, Versailles Saint-Quentin-en-Yvelines University, University of Paris-Saclay, Suresnes, France

Shakur-Still and colleagues investigated the effect of tranexamic acid on fibrinolysis and coagulation parameters in women with primary postpartum haemorrhage. The study was a randomised double-blind placebo-controlled trial and the inclusion criteria were the same as in the WOMAN clinical trial previously published by this team. Female participants were randomized to receive 1g intravenous tranexamic acid or placebo, and blood samples were taken before administration and 30 minutes later to assess coagulation and fibrinolysis parameters. On these samples, the results show a lower D-dimer concentration in the treated group than in the placebo group, after correction of the baseline concentration. These results are confirmed by the presentation of a meta-analysis including the results of a similar study conducted in another centre. This work is remarkable for the implementation of specialized methods of off-site biology under non-ideal conditions. The study is very well conducted and all methods and results are clearly reported. This study provides additional evidence on the action of tranexamic acid on fibrinolysis, which is the main mechanism involved in reducing bleeding and mortality. This work therefore further strengthens the interest in tranexamic acid for the treatment of haemorrhagic diseases, even if its pharmacology remains poorly known, in particular the optimal dose and administration method.

One of the technical aspects that could be clarified concerns the taking of blood samples. Each 15 ml sample was divided into three fractions: one 5 ml sample in a tube containing potassium EDTA for full blood count analysis and two 4.5 ml samples in tubes containing 0.5 ml sodium citrate for coagulation and rotational thromboelastometry. It would be interesting to know the nature of the primary tube used for sampling and the time frame within which the distribution between the three tubes was then carried out, in order to be able to assess the risk of initial coagulation activation.

Is the work clearly and accurately presented and does it cite the current literature?
Yes

Is the study design appropriate and is the work technically sound?
Yes

Are sufficient details of methods and analysis provided to allow replication by others?
Yes

If applicable, is the statistical analysis and its interpretation appropriate?
Yes

Are all the source data underlying the results available to ensure full reproducibility?
Yes

Are the conclusions drawn adequately supported by the results?
Yes

**Competing Interests:** No competing interests were disclosed.

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

---

**Referee Report 13 September 2018**

doi:10.21956/wellcomeopenres.16038.r33856

---

**Homa K. Ahmadzia**

Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, School of Medicine and Health Sciences, George Washington University, Washington, DC, USA

Summary: This article by Shakur-Still et al. studies the coagulation markers affected by tranexamic acid administration to women with clinically diagnosed postpartum hemorrhage using traditional and newer methods of laboratory analysis. This is a timely study as very limited data exists what happens in women with actual diagnosed postpartum hemorrhage and their coagulation parameters with and without antifibrinolytic therapy.

Introduction:
While it is true that coagulation parameters are affected after childbirth, as described, the wrong citation is provided for the statement 'within an hour of giving birth, there is a doubling of the plasma concentration of tissue plasminogen activator'.

Statistical analysis:
Would be prudent to provide the citation/rationale for using ML>15% as 'hyperfibrinolysis' as well as the other parameters/values cited.

Results:
Would be good to cite original trial methods or briefly describe randomization scheme employed for who got TXA versus placebo.

Table 1-Please provide statistical statement specifically how baseline parameters were similar (i.e. p>0.05) either in text or footnote other than the baseline CT values.

When making the statement 'no evidence of heterogeneity in the effect of TXA on fibrinolysis by time since delivery, etc' please provide actual data/analysis to support this finding.

Although the authors state no outlier was excluded, it may be worth examining in a subgroup analysis or sensitivity analysis what the ROTEM parameter differences would be if the outlier groups where not included - for example in the footnote in table 1 it states CT values for two women were 1814 and 3468.
seconds. This either means the test was run in error by the user or that the coagulopathy makes it difficult to interpret ML parameter.

Also, where these two women (from Table 1 in the footnote) included for the final comparison for ML?

Also one other key question is if the CONSORT flow chart states 80 women were included for primary outcome analysis - why are only 56/58 women shown data for d-dimer values in Table 2? Also it is interesting that only 49 patients per group were included for the LI60%. Were there technical issues that made it not possible to report out the LI60% parameter - if so then that could mean the ML parameter may also be less reliable.

If these are correct interpretations, please include in limitations section of discussion.

**Is the work clearly and accurately presented and does it cite the current literature?**
Partly

**Is the study design appropriate and is the work technically sound?**
Yes

**Are sufficient details of methods and analysis provided to allow replication by others?**
Yes

**If applicable, is the statistical analysis and its interpretation appropriate?**
Yes

**Are all the source data underlying the results available to ensure full reproducibility?**
Yes

**Are the conclusions drawn adequately supported by the results?**
Partly

**Competing Interests:** No competing interests were disclosed.

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.